Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer
Status:
Terminated
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
This trial provides a unique opportunity in that it combines genomic, proteomic and
pharmacogenomic assessments in patients receiving chemotherapy for advanced breast cancer. To
date no other trials have analyzed gene and protein expression at the same time points in the
same patient, combined with clinical outcome. Similar to previous attempts to predict
response based on expression of a single gene or protein, we expect that neither genomic or
proteomic profiling alone will be sufficient to optimize therapy. Rather, we expect an
iterative process that combines information gleaned from both platforms, modified to avoid
toxicity based on pharmacogenomics.
Details
Lead Sponsor:
Hoosier Cancer Research Network
Collaborators:
Baylor University Indiana University School of Medicine McGill University United States Department of Defense University of Colorado, Denver